The PSMA PET agent 64Cu SAR-bisPSMA detected a higher number of prostate cancer lesions and had a significantly higher SUVmax and SUVmean than 68Ga PSMA-11 PET/CT, according to initial data from a prospective multisite study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Could there be a new standard of care for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) detection of prostate cancer?
In a study that was presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers compared initial PSMA PET imaging with 68Ga PSMA-11 PET/CT to different dosing regimens of the PSMA PET agent 64Cu SAR-bisPSMA in 30 men with intermediate to high-risk prostate cancer. The study authors noted the dosing cohorts for 64Cu SAR-bisPSMA were 100 MBq, 150 MBq and 200 MBq. All PSMA PET scans were assessed by two blinded readers, according to the study.
The first reader diagnosed 63 prostate cancer lesions with 64Cu SAR-bisPSMA versus 51 lesions with 68Ga PSMA-11 PET/CT across all cohorts, and the second reader detected 34 lesions with 64Cu SAR-bisPSMA in comparison to 25 lesions with 68Ga PSMA-11 PET/CT, according to the phase 1, prospective, multisite study.
The researchers found that use of 64Cu SAR-bisPSMA resulted in a higher median SUVmax for the readers (30.3 and 41.7) in contrast to 68Ga PSMA-11 PET/CT (13.5 and 14.9). The study authors also noted that 64Cu SAR-bisPSMA had a significantly higher SUVmean (21.2 vs. 9.1 for the first reader and 28.4 vs. 9.94 for the second reader) and higher median tumor-to-background (TBR) ratios (53.6 vs. 24.3 for the first reader and 78.4 vs. 24.7 for the second reader) in comparison to 68Ga PSMA-11 PET/CT.
“More lesions were detected, and lesions exhibited higher SUVmax, SUVmean and TBR by 64Cu SAR-bisPSMA compared to 68Ga PSMA-11 in men being staged with intermediate- and high-risk (prostate cancer),” wrote study co-author Louise Emmett, M.D., the director of the Department of Theranostics and Nuclear Medicine at St. Vincent’s Hospital in Sydney, Australia, and colleagues.
(Editor’s note: For related content, see “Is Pre-Imaging Biopsy Necessary for Prostate Cancer Staging in Elderly Patients?,” “Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence” and “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer.”)
In contrast to other PSMA agents that have a single targeting functional group, the study authors said a key advantage of 64Cu SAR-bisPSMA is two PSMA-targeting functional groups.
“This can lead to improved tumor uptake and retention compared to PSMA monomers, which may be highly relevant in patients with suspected disease or suspected recurrence where the detection of lesions may lead to a change in management,” noted Emmett and colleagues.
(Editor’s note: For additional content and video interviews from the SNMMI 2023 conference, visit https://www.diagnosticimaging.com/conferences/snmmi .)
Clarity Pharmaceuticals, the developer of 64Cu SAR-bisPSMA, is reportedly planning to initiate a prospective phase 3 study of the agent later in 2023.
Reference
1. Lengyelova E, Wong V, Lenzo N, Parker M, Emmett L. Comparison of PET/CT in subjects with confirmed prostate cancer using 64Cu SAR-bisPSMA and 68Ga PSMA-11. Poster presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting, June 24-27, 2023, Chicago. https://am.snmmi.org/iMIS/SNMMI-AM?utm_source=dropdown&utm_medium=website&utm_id=AM2022&navItemNumber=581
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Interventional Radiology Study Shows Low Breast Cancer Recurrence 16 Months After Cryoablation
March 29th 2024In a cohort of patients with invasive breast cancer and tumor sizes ranging between 0.3 to 9 cm, image-guided cryoablation was associated with a 10 percent recurrence rate at 16 months, according to research recently presented at the Society of Interventional Radiology (SIR) conference.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Could Cloud-Based 'Progressive Loading' be a Boon for Radiology Workflows?
March 13th 2024The newly launched Progressive Loading feature, available through RamSoft’s OmegaAI software, reportedly offers radiologist rapid uploading of images that is faster than on-site networks and other cloud-based systems regardless of the network radiologists are using.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.